Sandoz signs development and license agreement with Vectura for a US inhaled generic (VR2081)
Jun 28, 2017
Sandoz AG has signed an exclusive development and license agreement with Jagotec AG, a subsidiary of Vectura Group, to develop a generic version of an existing major inhaled combination therapy for asthma and Chronic Obstructive Pulmonary Disease (COPD) (VR2081), using a pressurized metered dose inhaler (pMDI).
Peter Goldschmidt, President of Sandoz US, said: “The treatment of asthma and COPD place a significant cost burden on patients and the healthcare system in the US. We look forward to partnering with Vectura in the US to deliver in a timely manner on the next stage of our promising US respiratory pipeline, in the interests of all who stand to benefit.”
Under the terms of the agreement, Vectura will be responsible for developing the formulation and manufacture of clinical batches for use in pilot clinical studies, while Sandoz will be responsible for the clinical development, manufacture and commercialization of VR2081.
Peter concluded: “This development is a further indication that our strategy of focusing on value-added products, working together with external partners as and when appropriate, will add value for patients and payors and drive sustainable long-term growth.”